Blue Jet Healthcare Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹165Cr
- −20.7% YoY
- −53.5% QoQ
- Net profit
- ₹52Cr
- −10.3% YoY
- −42.9% QoQ
- Margin
- 33%
- 0 pp YoY
- −1 pp QoQ
Guidance rank: #28 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.
From Blue Jet Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments.
- Capacity expansions at Vizag (103 acres) and backward integration facility at Mahad are on track, with Phase-I at Vizag targeting completion by FY '28, adding 1,000 KL capacity over 2-3 years.
- Growth in the cardiovascular drug segment (notably Bempedoic Acid) is expected to continue, with triple-digit percentage growth reported and approvals in new markets like Japan expanding opportunities.
- Contrast media shipments faced transit delays but volumes and revenues are expected to normalize and sustain at FY '23 levels over the next 12-18 months.
2 more points from Blue Jet Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.
- Phase-I of Vizag project, with an approximate CAPEX of Rs. 1,000 crores, will have 4 blocks: 2 for Contrast Media, 1 for high-intensity Sweetener, and 1 multipurpose block including peptide fragments for GLPs; expected completion by FY '28.
- Backward integration facility at Mahad with a CAPEX of about Rs. 300 crores (increased from Rs. 250 crores due to automation); commissioning expected by H2 FY '26.
- A state-of-the-art R&D center is planned in Hyderabad at a cost of Rs. 40 crores to enhance capabilities including peptides, GLP1 intermediates, and biocatalysts.
2 more points from Blue Jet Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book visibility for contrast media (marketed product) remains stable as per management comments.
- The order book for intermediates, specifically for the NCE molecule, is noted to be encouraging.
- Commercial scale supply for iodinated intermediates expected to commence in Q4 of the financial year.
- Management emphasized a long-term view on capacity build-up aligned with orders, indicating visibility over 5 years, though ramp-up timing may vary by 12-18 months.
- Customer off-take and schedules cause some quarter-on-quarter volatility but overall order book remains solid.
- Growth prospects for Pharma Intermediate segment, including Bempedoic Acid and other chronic disease molecules, supported by good order visibility and new approvals.
2 more points from Blue Jet Healthcare Ltd's call on order book
Create a free account to keep reading this call
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Blue Jet Healthcare Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 165 | 208 | -20.7% | 355 | -53.5% |
| Operating profit (EBITDA) | 55 | 69 | -20.3% | 121 | -54.5% |
| Operating margin | 33% | 33% | 0 pp | 34% | -1 pp |
| Profit before tax | 69 | 77 | -10.4% | 123 | -43.9% |
| Net profit (PAT) | 52 | 58 | -10.3% | 91 | -42.9% |
| EPS (₹) | 3.01 | 3.36 | -10.4% | 5.26 | -42.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q2 FY26 results?
The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
